Weiss Ratings Reaffirms "Hold (C-)" Rating for Pfizer (NYSE:PFE)

Key Points

• Weiss Ratings has reaffirmed its "Hold (C-)" rating for Pfizer, indicating a cautious outlook on the stock.
• Analysts show mixed sentiments with Citigroup raising its price target on Pfizer from $25.00 to $26.00, while others maintain neutral or hold ratings.
• Pfizer's recent quarterly earnings exceeded expectations, with reported earnings of $0.78 per share and revenues of $14.65 billion, showcasing a year-over-year revenue increase of 10.3%.

Pfizer (NYSE:PFE - Get Free Report)'s stock had its "hold (c-)" rating reissued by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other equities analysts also recently issued reports about the stock. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Bank of America upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, UBS Group reaffirmed a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $28.41.

Pfizer Price Performance

PFE opened at $25.67 on Wednesday. The firm's fifty day moving average price is $24.79 and its two-hundred day moving average price is $24.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $145.95 billion, a price-to-earnings ratio of 13.65, a P/E/G ratio of 0.86 and a beta of 0.55. Pfizer has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wilsey Asset Management Inc. increased its position in shares of Pfizer by 12.0% in the third quarter. Wilsey Asset Management Inc. now owns 1,103,543 shares of the biopharmaceutical company's stock worth $28,118,000 after purchasing an additional 118,248 shares during the last quarter. Sheets Smith Investment Management bought a new position in shares of Pfizer in the third quarter worth approximately $204,000. Teamwork Financial Advisors LLC increased its position in shares of Pfizer by 27.1% in the third quarter. Teamwork Financial Advisors LLC now owns 81,894 shares of the biopharmaceutical company's stock worth $2,087,000 after purchasing an additional 17,456 shares during the last quarter. Fiduciary Alliance LLC increased its position in shares of Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company's stock worth $3,701,000 after purchasing an additional 46,043 shares during the last quarter. Finally, RDA Financial Network grew its position in Pfizer by 3.8% during the third quarter. RDA Financial Network now owns 70,311 shares of the biopharmaceutical company's stock valued at $1,792,000 after acquiring an additional 2,542 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.